Atlas Trials

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Clinical trial NCT03106077 · COMPLETED

Trial details

NCT number
NCT03106077
Sponsor
M.D. Anderson Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor NegativeFolate Receptor Alpha PositiveHER2/Neu NegativeProgesterone Receptor Negative
Start date
2017-06-05
Primary completion
2019-10-01
Enrollment
96

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.